Endocyte, Inc., a bio pharmaceutical company, develops therapies for the treatment of cancer and inflammatory diseases, has announced its results for first quarter of FY-2015.
The results shows, Revenues rise to $ 17,269,000 from $ 12,000, and EPS improves from -$0.26 to -$0.09 .
View the full earnings release here.